Last reviewed · How we verify
Trastuzumab, Capecitabine and Cisplatin
Trastuzumab, Capecitabine and Cisplatin is a Small molecule drug developed by Asan Medical Center. It is currently in Phase 2 development.
At a glance
| Generic name | Trastuzumab, Capecitabine and Cisplatin |
|---|---|
| Sponsor | Asan Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (PHASE3)
- Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer (PHASE3)
- A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer (PHASE3)
- Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) (PHASE2)
- A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE3)
- A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer (PHASE2, PHASE3)
- Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) (PHASE3)
- Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trastuzumab, Capecitabine and Cisplatin CI brief — competitive landscape report
- Trastuzumab, Capecitabine and Cisplatin updates RSS · CI watch RSS
- Asan Medical Center portfolio CI
Frequently asked questions about Trastuzumab, Capecitabine and Cisplatin
What is Trastuzumab, Capecitabine and Cisplatin?
Trastuzumab, Capecitabine and Cisplatin is a Small molecule drug developed by Asan Medical Center.
Who makes Trastuzumab, Capecitabine and Cisplatin?
Trastuzumab, Capecitabine and Cisplatin is developed by Asan Medical Center (see full Asan Medical Center pipeline at /company/asan-medical-center).
What development phase is Trastuzumab, Capecitabine and Cisplatin in?
Trastuzumab, Capecitabine and Cisplatin is in Phase 2.